CN113993850B - 整合应激反应途径的调节剂 - Google Patents

整合应激反应途径的调节剂 Download PDF

Info

Publication number
CN113993850B
CN113993850B CN202080045788.1A CN202080045788A CN113993850B CN 113993850 B CN113993850 B CN 113993850B CN 202080045788 A CN202080045788 A CN 202080045788A CN 113993850 B CN113993850 B CN 113993850B
Authority
CN
China
Prior art keywords
oxadiazol
chloro
acetamide
piperidin
fluorophenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080045788.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113993850A (zh
Inventor
H·阿顿
C·J·布朗
J·L·卡尔
S·康费斯-雷尼尔
M·科尔
M·弗罗娃
C·F·帕尔默
I·D·雷布尔
M·沙巴
S·萨德勒
J·夏因
D·S·沃尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evertec International Co ltd
Original Assignee
Evertec International Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evertec International Co ltd filed Critical Evertec International Co ltd
Publication of CN113993850A publication Critical patent/CN113993850A/zh
Application granted granted Critical
Publication of CN113993850B publication Critical patent/CN113993850B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080045788.1A 2019-04-23 2020-04-22 整合应激反应途径的调节剂 Active CN113993850B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19170504 2019-04-23
EP19170504.5 2019-04-23
EP19216875.5 2019-12-17
EP19216875 2019-12-17
PCT/EP2020/061150 WO2020216766A1 (en) 2019-04-23 2020-04-22 Modulators of the integrated stress response pathway

Publications (2)

Publication Number Publication Date
CN113993850A CN113993850A (zh) 2022-01-28
CN113993850B true CN113993850B (zh) 2024-03-29

Family

ID=70289816

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080045788.1A Active CN113993850B (zh) 2019-04-23 2020-04-22 整合应激反应途径的调节剂

Country Status (15)

Country Link
US (2) US12258338B2 (https=)
EP (1) EP3959198A1 (https=)
JP (2) JP7590343B2 (https=)
KR (1) KR20220004105A (https=)
CN (1) CN113993850B (https=)
AU (1) AU2020261234B2 (https=)
BR (1) BR112021020402A2 (https=)
CA (1) CA3137213A1 (https=)
CL (1) CL2021002772A1 (https=)
CO (1) CO2021014292A2 (https=)
IL (1) IL287379B2 (https=)
MX (2) MX2021012903A (https=)
PE (1) PE20220961A1 (https=)
SG (1) SG11202111119PA (https=)
WO (1) WO2020216766A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201245B (zh) 2017-09-01 2024-04-05 戴纳立制药公司 化合物、组合物和方法
CN111757739A (zh) 2017-12-13 2020-10-09 普拉西斯生物技术有限责任公司 整合应激反应路径抑制剂
AU2019282253A1 (en) 2018-06-05 2020-11-26 Altos Labs, Inc. Inhibitors of integrated stress response pathway
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
SG11202108552QA (en) * 2019-02-13 2021-09-29 Denali Therapeutics Inc Compounds, compositions and methods
MX2021012904A (es) * 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
WO2020252207A1 (en) 2019-06-12 2020-12-17 Praxis Biotech LLC Modulators of integrated stress response pathway
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents
CN115190813B (zh) 2020-03-11 2024-10-15 埃沃特克国际有限责任公司 整合应激反应途径的调节剂
EP4232153A1 (en) * 2020-10-22 2023-08-30 Evotec International GmbH Modulators of the integrated stress response pathway
RS66455B1 (sr) 2020-10-22 2025-02-28 Evotec Int Gmbh Modulatori puta integrisanog odgovora na stres
EP4232447A1 (en) 2020-10-22 2023-08-30 Evotec International GmbH Modulators of the integrated stress response pathway
US20230083885A1 (en) * 2021-04-02 2023-03-16 Praxis Biotech LLC Modulators of integrated stress response pathway
AU2023384649A1 (en) * 2022-11-21 2025-05-22 Shenzhen Zhongge Biological Technology Co., Ltd. Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof
CN116854623B (zh) * 2023-07-11 2025-08-05 齐鲁安替制药有限公司 一种阿维巴坦中间体的制备方法
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016001855A1 (en) * 2014-07-04 2016-01-07 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
CN108349984A (zh) * 2015-09-15 2018-07-31 葛兰素史密斯克莱知识产权（第2 号）有限公司 作为perk抑制剂的1-苯基吡咯烷-2-酮的衍生物
WO2019046779A1 (en) * 2017-09-01 2019-03-07 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
CN109563034A (zh) * 2016-06-08 2019-04-02 葛兰素史密斯克莱知识产权发展有限公司 化学化合物
CN109563071A (zh) * 2016-06-08 2019-04-02 葛兰素史密斯克莱知识产权发展有限公司 作为atf4途径抑制剂的化学化合物
WO2019090081A1 (en) * 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
WO2019183589A1 (en) * 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639761B1 (en) 1999-12-02 2003-10-28 Seagate Technology Llc Micro-actuator damping and humidity protection
AU2001233044A1 (en) * 2000-01-28 2001-08-07 Akkadix Corporation Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles
JP2007532672A (ja) 2004-04-16 2007-11-15 ウェイン ステート ユニバーシティ 三置換２−ベンズヒドリル−５−ベンジルアミノ−テトラヒドロ−ピラン−４−オール、及び６−ベンズヒドリル−４−ベンジルアミノ−テトラヒドロ−ピラン−３−オール類縁体、及び新規３，６−二置換ピラン誘導体
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
EP3649108A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
BR112020000122A2 (pt) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças
DE102017213834A1 (de) * 2017-08-08 2019-02-14 Robert Bosch Gmbh Sende-/Empfangseinrichtung für ein Bussystem und Verfahren zur Reduzierung einer Schwingneigung beim Übergang zwischen unterschiedlichen Bitzuständen
CA3071024A1 (en) 2017-08-09 2019-02-14 Denali Therapeutics Inc. Compounds, compositions and methods
CA3080808A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
WO2019090074A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
WO2019090088A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
WO2019090090A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
AU2018358157B2 (en) 2017-11-02 2023-03-09 Abbvie Inc. Modulators of the integrated stress pathway
CN111757739A (zh) 2017-12-13 2020-10-09 普拉西斯生物技术有限责任公司 整合应激反应路径抑制剂
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016001855A1 (en) * 2014-07-04 2016-01-07 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
CN108349984A (zh) * 2015-09-15 2018-07-31 葛兰素史密斯克莱知识产权（第2 号）有限公司 作为perk抑制剂的1-苯基吡咯烷-2-酮的衍生物
CN109563034A (zh) * 2016-06-08 2019-04-02 葛兰素史密斯克莱知识产权发展有限公司 化学化合物
CN109563071A (zh) * 2016-06-08 2019-04-02 葛兰素史密斯克莱知识产权发展有限公司 作为atf4途径抑制剂的化学化合物
WO2019046779A1 (en) * 2017-09-01 2019-03-07 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
WO2019090081A1 (en) * 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
WO2019183589A1 (en) * 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage;Bobrovnikova-Marjon, E.等;Oncogene;第29卷;第3881-3895页 *
REGISTRY[Online];Columbus,Ohio,US;REGISTRY;2286582-02-1，2286576-77-8，1396491-78-3，1212728-70-5，1212685-85-2，1212683-11-8，1212664-04-4，1212658-99-5，1212634-69-9，1212633-89-0，1212628-07-3，1212619-73-2，1212618-04-6，1212561-17-5，1212554-50-1，1212507-42-0 *
非酒精性脂肪变性肝细胞模型中ATF4基因的表达及其意义;王万东 等;第三军医大学学报;第32卷(第14期);第1487-1490页 *

Also Published As

Publication number Publication date
AU2020261234A1 (en) 2021-11-11
WO2020216766A1 (en) 2020-10-29
IL287379B1 (en) 2025-07-01
AU2020261234B2 (en) 2026-02-05
MX2024015479A (es) 2025-02-10
BR112021020402A2 (pt) 2021-12-07
CA3137213A1 (en) 2020-10-29
PE20220961A1 (es) 2022-06-10
JP7590343B2 (ja) 2024-11-26
US12258338B2 (en) 2025-03-25
MX2021012903A (es) 2022-01-18
JP2025024086A (ja) 2025-02-19
EP3959198A1 (en) 2022-03-02
KR20220004105A (ko) 2022-01-11
CN113993850A (zh) 2022-01-28
CL2021002772A1 (es) 2022-07-29
CO2021014292A2 (es) 2022-04-29
US20250188071A1 (en) 2025-06-12
US20220227747A1 (en) 2022-07-21
JP2022530049A (ja) 2022-06-27
IL287379B2 (en) 2025-11-01
IL287379A (en) 2021-12-01
SG11202111119PA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
CN113993850B (zh) 整合应激反应途径的调节剂
JP7699595B2 (ja) 統合的ストレス応答経路の調節因子
AU2021367147B2 (en) Modulators of the integrated stress response pathway
EP4232447A1 (en) Modulators of the integrated stress response pathway
CN116964047B (zh) 整合应激反应途径的调节剂
HK40068295B (zh) 整合应激反应途径的调节剂
HK40068295A (en) Modulators of the integrated stress response pathway
EA051407B1 (ru) Модуляторы пути интегрированного ответа на стресс
EA050793B1 (ru) Модуляторы пути интегрированного ответа на стресс
HK40073491B (zh) 整合应激反应途径的调节剂
EA048846B1 (ru) Модуляторы пути интегрированного ответа на стресс
EA048763B1 (ru) Модулятор пути интегрированного ответа на стресс и его применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068295

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant